Highlights

• Organigram to acquire Aurora in a deal valued at about $561 million, with closing expected in January 2027

• Aurora shareholders may elect $7.80 in cash, 5.8626 Organigram shares per Aurora share, or a mix, subject to caps

• Second quarter net Revenue of $86.0 million; international medical revenue up to $61.4 million; adjusted EBITDA of $14.0 million

Aurora Cannabis Inc. (TSX:ACB) entered into a definitive arrangement agreement with Organigram Global Inc. in an announcement made on Tuesday, November third, and followed it with a management discussion and analysis for the fiscal second quarter, prepared as of the next day. Together, the two documents give shareholders a view of both a pending change of control and the operating performance of a company that has repositioned itself around medical cannabis.

The Terms on the Table

Under the agreement, Organigram would acquire Aurora in a transaction valuing the Canadian producer at about five hundred sixty-one million dollars. Each Aurora Shareholder may elect to receive seven dollars and eighty cents in cash, or a fixed number of Organigram shares of just under six per Aurora share, or a combination, subject to proration. Total cash is capped at about two hundred fifty-four million dollars, and the number of Organigram shares to be issued is capped at roughly two hundred six million.

Both boards unanimously support the transaction. The offer represents a premium of ninety-three percent to Aurora's share price as of a date in August, and a premium of about twenty-one percent to the implied value of an unsolicited bid that had been launched by a United States operator and amended in early October. Organigram projects synergies above fifty million dollars from cross-selling, procurement scale and related sources. Completion is expected in January and requires shareholder approval, regulatory clearances and permission from the Supreme Court of British Columbia.

Financing, Approvals and Ownership

The joint announcement set out how the cash portion would be funded. Organigram's largest shareholder, the tobacco group BAT, agreed to subscribe for a large private Placement of Organigram shares at a price of one dollar and thirty-three cents, raising roughly one hundred eighty-seven million dollars. ATB Financial also committed up to two hundred ten million dollars in senior secured Credit facilities, including a term Tranche available at closing. On a fully diluted basis, Aurora shareholders would own roughly one third of the combined company's economic interest and a larger share of its votes.

Approvals are layered. Aurora needs at least two thirds of the votes cast at a special meeting, plus a majority of the minority under Canadian securities rules governing related party transactions. Organigram needs a majority of votes cast excluding its major shareholder, which has signed an irrevocable voting agreement. German foreign Investment clearance is also required, and meetings are expected in December.

A Contested Takeover Environment

The agreement follows a contested process. The United States operator launched its unsolicited offer in August after Aurora's board declined to negotiate, and Aurora's board urged shareholders to reject it. In the management discussion and analysis, the board repeated that shareholders should reject the unsolicited bid and not tender their shares, noting that the bid is scheduled to expire in early December. The bidder has said that its enhanced proposal remains open and that key terms of the friendly deal, such as any break fee and governance arrangements, were not yet disclosed.

For investors following Cannabis Stocks, the episode illustrates how consolidation pressure has grown among Canadian licensed producers. Slower domestic growth, price compression and high fixed costs have encouraged larger players to seek scale, while access to international medical markets has become a strategic prize.

Second Quarter Operating Results

Aurora reports in Canadian dollars. Net revenue for the three months ended in September was about eighty-six million dollars, compared with roughly seventy-nine million a year earlier. Medical cannabis revenue rose to about eighty-two and a half million dollars from seventy and a half million dollars. Reported gross Margin was forty-four percent, up from forty percent, and gross margin before Fair Value adjustments was fifty-one percent.

Adjusted EBITDA was about fourteen million dollars, down from roughly fifteen and a half million dollars, because adjusted selling, general and administrative expense rose to about thirty-seven million dollars. The net loss was about twenty-one million dollars, compared with a loss of about fifty-three million dollars a year earlier, though the prior figure included a large loss from discontinued operations.

Revenue Mix Shifts Abroad

The composition of revenue changed markedly. International medical revenue climbed to about sixty-one million dollars from about forty-three million, led by Germany and Poland. Canadian medical revenue fell to about twenty-one million dollars from about twenty-eight million, which management attributed to federal reimbursement changes that took effect in April. Consumer revenue dropped to under two million dollars as that channel was wound down.

This reshaping means that most of the Business now depends on foreign regulated markets, where pricing has remained firmer than in the Canadian recreational channel. It also exposes the company to European regulatory decisions, currency movements and the logistics of exporting from Canadian facilities. Acquisitions this year, including a European flower processor and two businesses in the United Kingdom, were described as expanding good Manufacturing practice capacity and pharmacy distribution.

Liquidity and Controls

At the end of September, Aurora held about sixty-six million dollars in cash and equivalents, about eighteen million dollars in short-term investments and about forty-nine million dollars in restricted cash. Working Capital was roughly three hundred seven million dollars, and Lease liabilities were the only reported debt, at about twenty-one million dollars. Free Cash Flow was negative by about seventeen and a half million dollars, an improvement from a Deficit near forty million a year earlier. The company also retains remaining capacity under an at-the-market Equity programme of about eighty million American dollars.

The company expects roughly forty-seven million dollars of restricted self-insurance cash to become available when the wind-up of a segregated cell completes, which it targets for the third fiscal quarter. Separately, management disclosed that disclosure controls were not effective because of a material weakness related to biological asset and Inventory Valuation first identified at the end of March, and remediation continues. Such weaknesses do not by themselves imply misstatement, but they Warrant attention in any transaction that depends on valuation.

Risks and Next Steps

Several uncertainties surround the transaction. Shareholders must approve the arrangement, the court must grant an order, and regulators must clear the combination. A competing bidder remains active, so the possibility of a revised offer cannot be excluded. If the deal proceeds, the stock-election component also links outcomes to Organigram's share price at closing.

Operationally, the decline in Canadian medical revenue and the wind-down of the consumer channel reduce domestic exposure, and the pace at which international sales can offset that shift will matter. The balance of cash and share consideration will also matter to taxable Canadian holders, who should consult the circular for the tax treatment applicable to registered accounts such as a TFSA or RRSP.

Index and Market Context

Aurora trades on the Toronto Stock Exchange and Nasdaq. Its weight in the [S&P/TSX Composite Index] is small, and the shares have reacted more to takeover headlines than to macroeconomic data. The Bank of Canada's rate path influences financing conditions across the sector, yet the near-term price drivers are likely to be the shareholder vote timetable, any amended competing offer and the next quarterly report.